EN
HI

Mankind Pharma Share price

MANKIND

HealthcareLarge

2467.7

5.90 (0.24%)
NSE
BSE
Last updated on 30 May, 2025 | 15:42 IST
BUYSELL
Today's High

2548.00

Today's Low

2451.10

52 Week Low

1901.05

52 Week High

3054.80

The current prices are delayed, login to your account for live prices

Mankind Pharma Chart

Mankind Pharma Share Key Metrics

Volume
8.22 L
Market Cap
101812.00 CR
LTQ@LTP
1@2467.70
ATP
2493.91
Var Margin
16.37 %
Circuit Range
2215.7-2707.9
Delivery %
58.72 %
Value
204.89 CR
ASM/GSM
No
Market Lot
1

Mankind Pharma Futures & Options

MANKIND-EQ

2467.7

5.9 (0.24%)

Mankind Pharma Option Chain

View Price, OI, Greeks & More...
View Allee

26JUN25

24.70

2470.00 (Infinity%)

31JUL25

24.84

2484.40 (Infinity%)

28AUG25

25.21

2520.80 (Infinity%)

MANKIND|26JUN25 CE 2450.00

100.00

-16.55 (-14.2%)

MANKIND|26JUN25 PE 2500.00

110

-8.75 (-7.37%)

Mankind Pharma Corporate Actions

DateAgenda
2025-05-21Audited Results
2025-01-23Quarterly Results
DateEvent TypeAgenda
2025-05-21Board MeetingAudited Results
2025-01-23Board MeetingQuarterly Results

Mankind Pharma News

Mankind Pharma inks licensing pact with Innovent to commercialise Sintilimab in India

Dec 26 2024 19:21:53

Mankind Pharma partners with Innovent to aid cancer treatment in India

Dec 26 2024 12:06:53

Mankind Pharma shares in focus after co launches Rs 3,000 crore QIP

Dec 17 2024 09:36:52

Dr Reddy's Labs, Mankind Pharma riding on strong growth drivers

Nov 06 2024 16:42:04
Read More

About Mankind Pharma

NSE : 15380  
BSE : 543904  
ISIN : INE634S01028  

Our Company was incorporated on July 3 1991 as a private limited company under the Companies Act 1956 with the name “Mankind Pharma Private Limited” pursuant to a certificate of incorporation granted by the Registrar of Companies Delhi and Haryana at New Delhi (“RoC”). Pursuant to the conversion of our Company to a public limited company and as approved by our Shareholders pursuant to a special resolution dated July 14 2005 the name of our Company was changed to “Mankind Pharma Limited” and the RoC issued a fresh certificate of incorporation on April 13 2006.Major events and milestones:2004 Entered the chronic pharmaceutical segment with the launch of ‘Amlokind’ tablets and ‘Glimestar’tablets amongst others2005 -Set up our first manufacturing facility at Paonta Sahib Himachal Pradesh-Entered the ophthalmic pharmaceutical segment with the launch of ‘Lubistar Eye Drops’ and ‘Tobastar Eye Drops’ amongst others2007 -Entered the consumer healthcare segment with the launch of ‘Manforce’ brand-Entered the animal healthcare segment with launch of ‘Bandykind’ and ‘Ceftiforce’ amongst othersRaised ? 720 million from Monet Limited2009 Set up our manufacturing facility at Unit II Paonta Sahib Himachal Pradesh2010 Launched ‘Preganews’ brand in the consumer healthcare segment2012 Setup our first R&D centre at IMT Manesar Haryana2014 -Acquired Shree Jee Laboratory Private Limited (along with its API manufacturing site situated at Behror Rajasthan)-Set up our manufacturing facility at Unit III Paonta Sahib Himachal Pradesh2015 -Incorporated our Subsidiary Lifestar Pharma LLC in the US-Incorporated our Subsidiary Mankind Pharma Pte. Limited in Singapore2017 Set up our manufacturing facility in Sikkim2018 Our manufacturing facility at Paonta Sahib Himachal Pradesh was inspected by the USFDA for the first time2019 Entered the female infertility segment with the launch of ‘Dydroboon’ tablets2020 -Incorporated our Subsidiary Lifestar Pharmaceuticals Private Limited in Nepal-Launched a dedicated specialty therapeutic division for cardiovascular diseases drugs segment with launch of ‘Cilaheart’ tablets and ‘Statpure’ tablets-Launched a dedicated specialty therapeutic division for diabetes pharmaceuticals segment with launch of ‘Zukanorm’ tablets2021 -Incorporated our Subsidiary Mankind Pharma FZ-LLC in Dubai UAE-Launched a specialty division for therapeutic respiratory pharmaceuticals with launch of ‘Mlife’ tablets-Entered the specialty therapeutic neuro/central nervous system pharmaceuticals segment with launch of ‘Trugaba-NT’ tablets and ‘Prebris-MNT’ tablets2022 -Acquired the pharmaceutical formulations brands in India and Nepal from Panacea Biotec Pharma Limited and Panacea Biotec Limited-Entered into transplant segment with the launch of ‘Pangraf Capsules’ and ‘Mycept’ tablets amongst others-Entered into oncology segment with the launch of ‘Pacliall’ injection amongst others-Acquired the brands ‘Daffy’ and ‘Combihale’ from Dr. Reddy’s Laboratories-Our Subsidiary Mankind Life Sciences Private Limited acquired 90.00% of the issued subscribed and paid-up share capital of Upakarma Ayurveda Private Limited.

Mankind Pharma Management

NamePosition
Mr. Ramesh Juneja Chairman & Wholetime Director
Mr. Rajeev Juneja Vice Chairman & Mng.Director
Ms. Sheetal Arora WholeTime Director & CEO
Mr. Satish Kumar Sharma Whole Time Director
Mr. Vivek Kalra Independent Director
Read More

Mankind Pharma FAQs

The Buying Price of Mankind Pharma share is 2467.7 For live prices and instant trading, you can log in to your Choice trading account or open a Free Demat account with Choice.

To buy Mankind Pharma share log in to your Choice trading account, or open a Choice Demat account, then add funds, search the company name, select your order type, and place your trade.

The Price-to-earnings (P/E) ratio of Mankind Pharma shares is 51.27. You can compare it with the sector average for relative valuation.

The Price to Book (P/B) ratio Mankind Pharma shares is 7.12. Useful to assess the stock's value relative to its book value.

To assess Mankind Pharma’s valuation compare Sector P/E, P/B which are 37.05 & 4.02 with sector averages, along with growth rates and financial metrics.

The Market Cap of Mankind Pharma is 101812.00 CR. It indicates the company's size category and trading liquidity.

The 52 week high and low prices of Mankind Pharma share price is 3054.80 & 1901.05. They indicate price extremes, trading ranges, volatility measures, potential support/resistance, and price momentum.